Navigation Links
Argos Therapeutics' Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System
Date:10/4/2011

DURHAM, N.C., Oct. 4, 2011 /PRNewswire/ -- Argos Therapeutics, Inc. today announced that its late scientific co-founder and scientific advisor Ralph M. Steinman, M.D., was awarded the Nobel Prize in medicine for the discovery of dendritic cells as critical sentinels of the immune system.

Dr. Steinman's discovery of dendritic cells and his research of dendritic cell biology and the role of dendritic cells in adaptive immunity have led to the development of Argos' core technology, Arcelis. 

"The Nobel Prize is further validation of the lifelong work of Dr. Steinman and Argos looks forward to continuing his work through further development of its dendritic cell-based immunotherapies," said Charles Nicolette, Ph.D., Argos' chief scientific officer and vice president of research and development. "We are planning to advance our Arcelis immunotherapy for the treatment of metastatic renal cell carcinoma, AGS-003, into a global Phase 3 clinical trial."

Dr. Nicolette added, "We extend our deepest condolences to Dr. Steinman's family for his untimely passing."

Dr. Steinman was a Henry G. Kunkel Professor at The Rockefeller University and a senior physician at The Rockefeller University Hospital. His research focused on the immune system including the human immune system in the setting of several diseases. His research aimed at developing vaccines and immune-based therapies for tumors, infections and autoimmune diseases.  Dr. Steinman received a B.S. degree from McGill University and an M.D. from Harvard University.

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV.  

Contact:
Jeff Abbey
Argos Therapeutics
(919) 287-6308
jabbey@argostherapeutics.com  


'/>"/>
SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering
2. Argos Therapeutics Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
3. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
4. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
5. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
6. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
7. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
8. Orexigen® Therapeutics Presents Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
9. Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
10. Independent Radiology Assessment Panel Results Confirm Statistical Significance of Response and Progression Endpoints of Cell Therapeutics Pixantrone PIX301 Pivotal Trial
11. Silence Therapeutics Signs siRNA Delivery Collaboration With Top 10 Pharma Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/11/2017)... 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading ... data solutions, today announced that it will release its ... host a conference call at 9:00am ET. The Company ... results and its strategy and outlook for the remainder ... Erez Raphael , Chief Executive Officer, and Zvi ...
(Date:8/7/2017)... 2017 Insightin Health, provider of data-driven ... engagement, announced the selection of Michael Wood ... effective as of February 2017. In this role, Wood ... for our clients. Wood brings with him more ... business analytics within the healthcare industry. Wood formerly ...
Breaking Medicine Technology:
(Date:8/18/2017)... , ... August 18, 2017 , ... ... services and financial consultations to communities throughout the greater DC region, is inaugurating ... the goal of rescuing local animals and training them to be companions for ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... and financial planning services to communities in east Texas, is launching a regional ... Tumor Foundation. , Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has ...
(Date:8/18/2017)... John, IN (PRWEB) , ... August 18, 2017 , ... ... to communities in northwest Indiana, is campaigning in support of Campagna Academy in a ... referred to as the “Hoosier Boys’ Town of Indiana,” Campagna Academy is a nonprofit ...
(Date:8/18/2017)... TX (PRWEB) , ... August 18, 2017 , ... The ... communities in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized to ... husband. , In early June of this year, Christina and her children returned from ...
(Date:8/18/2017)... ... August 18, 2017 , ... With over ... in bioidentical hormone replacement therapy and integrative medicine, has become a frontrunner for ... aging, such as menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded ...
Breaking Medicine News(10 mins):